Deciding if Compass Therapeutics shares are worth purchasing requires balancing promising early-stage cancer drug pipelines and a healthy cash runway against the traditional risks of clinical-stage biotech investing. To help tailor this context: What is your total portfolio risk tolerance, and what target allocation do you maintain for high-beta biotechnology assets?